meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA)
3
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab alone
versus all
vs immune chekpoint inhibitors
vs Immune checkpoint association
vs nivolumab plus ipilimumab
vs non active control
vs placebo
All patients
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
RFS/DFS
deaths (OS)
metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA)
metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA)
versus placebo
pembrolizumab alone vs. placebo
1
certainty unassessable
-42%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open